{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:40:37Z","timestamp":1770889237708,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"clinical special application research of capital of China","award":["Z171100001017172"],"award-info":[{"award-number":["Z171100001017172"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12886-018-1016-7","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T12:11:00Z","timestamp":1546949460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion: a meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Lixiong","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-5482","authenticated-orcid":false,"given":"Qian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"issue":"4","key":"1016_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.survophthal.2010.11.006","volume":"56","author":"JP Ehlers","year":"2011","unstructured":"Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol. 2011;56(4):281\u201399.","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"1016_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archopht.1996.01100130537006","volume":"114","author":"The Eye Disease Case-Control Study Group","year":"1996","unstructured":"The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996;114(5):545\u201354.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1016_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/02713680701851902","volume":"33","author":"J Rehak","year":"2008","unstructured":"Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33(2):111\u201331.","journal-title":"Curr Eye Res"},{"issue":"3","key":"1016_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0161-6420(93)31633-7","volume":"100","author":"J Zhao","year":"1993","unstructured":"Zhao J, Sastry SM, Sperduto RD, Chew EY, Remaley NA. Arteriovenous crossing patterns in branch retinal vein occlusion. The eye disease case-control study group. Ophthalmology. 1993;100(3):423\u20138.","journal-title":"Ophthalmology"},{"key":"1016_CR5","first-page":"371","volume":"79","author":"WR Green","year":"1981","unstructured":"Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc. 1981;79:371\u2013422.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"3","key":"1016_CR6","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1167\/iovs.08-2510","volume":"50","author":"M Funk","year":"2009","unstructured":"Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009;50(3):1025\u201332.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"1016_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/ICU.0b013e3283524148","volume":"23","author":"P Hahn","year":"2012","unstructured":"Hahn P, Fekrat S. Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol. 2012;23(3):175\u201381.","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"1016_CR8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ajo.2005.12.011","volume":"141","author":"SD Chen","year":"2006","unstructured":"Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2006;141(5):876\u201383.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1016_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1167\/iovs.10-5285","volume":"52","author":"JE Chang-Lin","year":"2011","unstructured":"Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1016_CR10","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"JA Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134\u20131146.e3.","journal-title":"Ophthalmology"},{"issue":"12","key":"1016_CR11","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","volume":"118","author":"JA Haller","year":"2011","unstructured":"Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453\u201360.","journal-title":"Ophthalmology"},{"issue":"12","key":"1016_CR12","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","volume":"120","author":"SR Boyd","year":"2002","unstructured":"Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA, Martin JF, Hykin PG. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002;120(12):1644\u201350.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"1016_CR13","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.ajo.2007.07.038","volume":"144","author":"DC Ferrara","year":"2007","unstructured":"Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol. 2007;144(6):864\u201371.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1016_CR14","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, Investigators C. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124\u201333 e1121.","journal-title":"Ophthalmology"},{"issue":"7","key":"1016_CR15","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/bjophthalmol-2014-306543","volume":"99","author":"R Narayanan","year":"2015","unstructured":"Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH, Group Ms. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL report no. 1. Br J Ophthalmol. 2015;99(7):954\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"1016_CR16","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3928\/23258160-20150909-09","volume":"46","author":"R Rajagopal","year":"2015","unstructured":"Rajagopal R, Shah GK, Blinder KJ, Altaweel M, Eliott D, Wee R, Cooper B, Walia H, Smith BT, Joseph DP. Bevacizumab versus Ranibizumab in the treatment of macular edema due to retinal vein occlusion: 6-month results of the CRAVE study. Ophthalmic Surg Lasers Imaging Retina. 2015;46(8):844\u201350.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"1016_CR17","volume":"9","author":"D Gewaily","year":"2015","unstructured":"Gewaily D, Muthuswamy K, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2015;9:CD007324.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1016_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/jcpt.12551","volume":"42","author":"T Qian","year":"2017","unstructured":"Qian T, Zhao M, Xu X. Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: a meta-analysis. J Clin Pharm Ther. 2017;42(5):519\u201329.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"1016_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1055\/s-0042-123025","volume":"234","author":"H Gerding","year":"2017","unstructured":"Gerding H. Results of a meta-analysis on Intravitreal anti-VEGF treatment of macular Oedema secondary to branch retinal vein occlusion (BRVO). Klin Monatsbl Augenheilkd. 2017;234(4):551\u20135.","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1016_CR20","doi-asserted-by":"publisher","unstructured":"Bandello F, Augustin A, Tufail A, Leaback R. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. Eur J Ophthalmol. 2018;1120672117750058. \n                    https:\/\/doi.org\/10.1177\/1120672117750058\n                    \n                  .","DOI":"10.1177\/1120672117750058"},{"key":"1016_CR21","doi-asserted-by":"publisher","unstructured":"Feltgen N, Hattenbach LO, Bertelmann T, Callizo J, Rehak M, Wolf A, Berk H, Eter N, Lang GE, Pielen A, et al. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study. Acta Ophthalmol. 2018. \n                    https:\/\/doi.org\/10.1111\/aos.13770\n                    \n                  .","DOI":"10.1111\/aos.13770"},{"issue":"1","key":"1016_CR22","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1111\/aos.13381","volume":"96","author":"LO Hattenbach","year":"2018","unstructured":"Hattenbach LO, Feltgen N, Bertelmann T, Schmitz-Valckenberg S, Berk H, Eter N, Lang GE, Rehak M, Taylor SR, Wolf A, et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol. 2018;96(1):e10\u20138.","journal-title":"Acta Ophthalmol"},{"key":"1016_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ajo.2016.04.020","volume":"169","author":"H Hoerauf","year":"2016","unstructured":"Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, et al. Clinical efficacy and safety of Ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): a European label study. Am J Ophthalmol. 2016;169:258\u201367.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1016_CR24","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"6","key":"1016_CR25","doi-asserted-by":"publisher","first-page":"e007527","DOI":"10.1136\/bmjopen-2014-007527","volume":"5","author":"SA Regnier","year":"2015","unstructured":"Regnier SA, Larsen M, Bezlyak V, Allen F. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open. 2015;5(6):e007527.","journal-title":"BMJ Open"},{"issue":"6","key":"1016_CR26","first-page":"1234","volume":"8","author":"Y Sun","year":"2015","unstructured":"Sun Y, Qu Y. Comparison of intravitreal bevacizumab with intravitreal triamcinolone acetonide for treatment of cystoid macular edema secondary to retinal vein occlusion: a meta-analysis. Int J Ophthalmol. 2015;8(6):1234\u20139.","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"1016_CR27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000335047","volume":"227","author":"H Noma","year":"2012","unstructured":"Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K. Inflammatory factors in major and macular branch retinal vein occlusion. Ophthalmologica. 2012;227(3):146\u201352.","journal-title":"Ophthalmologica"},{"issue":"11","key":"1016_CR28","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s00417-010-1486-7","volume":"248","author":"H Noma","year":"2010","unstructured":"Noma H, Funatsu H, Mimura T, Harino S, Eguchi S, Hori S. Pigment epithelium-derived factor and vascular endothelial growth factor in branch retinal vein occlusion with macular edema. Graefes Arch Clin Exp Ophthalmol. 2010;248(11):1559\u201365.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1016_CR29","doi-asserted-by":"publisher","first-page":"438412","DOI":"10.1155\/2013\/438412","volume":"2013","author":"A Deobhakta","year":"2013","unstructured":"Deobhakta A, Chang LK. Inflammation in retinal vein occlusion. Int J Inflam. 2013;2013:438412.","journal-title":"Int J Inflam"},{"issue":"9","key":"1016_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1442-9071.2009.01909.x","volume":"36","author":"SP Park","year":"2008","unstructured":"Park SP, Ahn JK. Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion. Clin Exp Ophthalmol. 2008;36(9):831\u20135.","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"1016_CR31","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"JA Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, et al. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Ophthalmology. 2010;117(6):1134\u20131146.e1133.","journal-title":"Ophthalmology"},{"issue":"7","key":"1016_CR32","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1167\/iovs.11-9119","volume":"53","author":"S Nakao","year":"2012","unstructured":"Nakao S, Arima M, Ishikawa K, Kohno R, Kawahara S, Miyazaki M, Yoshida S, Enaida H, Hafezi-Moghadam A, Kono T, et al. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis. Invest Ophthalmol Vis Sci. 2012;53(7):4323\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1016_CR33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/bjo.86.4.363","volume":"86","author":"AP Adamis","year":"2002","unstructured":"Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86(4):363\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"1016_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1586\/17512433.2014.884458","volume":"7","author":"MW Stewart","year":"2014","unstructured":"Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol. 2014;7(2):167\u201380.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"1016_CR35","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.ophtha.2010.12.034","volume":"118","author":"WE Smiddy","year":"2011","unstructured":"Smiddy WE. Economic considerations of macular edema therapies. Ophthalmology. 2011;118(9):1827\u201333.","journal-title":"Ophthalmology"},{"issue":"1","key":"1016_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12886-018-0779-1","volume":"18","author":"Y He","year":"2018","unstructured":"He Y, Ren XJ, Hu BJ, Lam WC, Li XR. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmol. 2018;18(1):121.","journal-title":"BMC Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-018-1016-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-018-1016-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-018-1016-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T19:09:31Z","timestamp":1578424171000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-018-1016-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1016"],"URL":"https:\/\/doi.org\/10.1186\/s12886-018-1016-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"assertion":[{"value":"25 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"8"}}